FEMASYS INC 8-K

What Happened
Femasys Inc. announced in an 8-K that it hired John Canning as Chief Operating Officer, effective March 30, 2026. Mr. Canning, age 52, joins from Terumo Aortic (COO, Apr 2017–Feb 2026) and previously held senior operations roles at Bolton Medical and Medtronic. The company entered into an employment agreement that sets his annual base salary, bonus opportunity, equity inducement and certain severance protections.

Key Details

• Base salary: $450,000 per year (effective March 30, 2026).
• Annual bonus: Eligible for company annual bonus program with a target of 40% of base salary.
• Inducement equity: Nonstatutory stock option to purchase 150,000 shares granted March 30, 2026; exercise price = Nasdaq closing price on grant date; vests 25% after 1 year, then 25% each year for the next 3 years (4-year schedule).
• Severance/termination: If terminated without cause or he resigns for good reason, he is eligible for unpaid prior-year bonus, nine months of base salary continuation, and nine months of subsidized COBRA premiums (subject to conditions, including execution of a release).
• Benefits: Eligible to participate in the company’s 401(k), health plans and other employee benefits on standard terms.

Why It Matters
This is a material executive change affecting Femasys’ operational leadership — hiring an experienced medical-device operations executive may support scaling manufacturing and commercialization efforts. The inducement option and severance terms are standard tools to attract senior hires; the option vests over four years and the exercise price equals the market close on the grant date, so it carries no immediate intrinsic value. Investors should note the potential for future long-term incentive awards and monitor subsequent company updates on operations, commercialization progress, and any additional executive compensation disclosures.